Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.

Autor: Smrkovski OA; Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA., Essick L; Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA., Rohrbach BW; Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA., Legendre AM; Department of Small Animal Clinical Sciences, The University of Tennessee, C247 Veterinary Teaching Hospital, Knoxville, TN, USA.
Jazyk: angličtina
Zdroj: Veterinary and comparative oncology [Vet Comp Oncol] 2015 Sep; Vol. 13 (3), pp. 314-21. Date of Electronic Publication: 2013 Jul 12.
DOI: 10.1111/vco.12053
Abstrakt: Masitinib mesylate is a tyrosine kinase inhibitor approved for the treatment of gross, non-metastatic grade II and III canine mast cell tumours (MCTs). This study evaluated the use of masitinib as a frontline and rescue agent for metastatic and non-metastatic canine MCTs. Identification of toxicities and prognostic factors in these dogs was of secondary interest. Twenty-six dogs were included in this study. The overall response rate to masitinib was 50%. The median survival time for dogs that responded to masitinib was 630 days versus 137 days for dogs that did not respond (P = 0.0033). Toxicity was recorded in 61.5% of treated dogs, but the majority of adverse events were mild and self-limiting. Response to masitinib, not tumour grade, stage or location, was the most significant prognostic factor for survival in dogs with MCTs.
(© 2013 Blackwell Publishing Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje